Low-dose treatment strategies
- PMID: 2871010
Low-dose treatment strategies
Abstract
Dose-comparison studies in chronic, continuously hospitalized patients show that megadoses of antipsychotic drugs are reasonably well tolerated. These findings, together with dose-comparison studies in acute patients, support the notion (and current practice) that the therapeutic index of antipsychotic drugs is wide. Recent work with outpatients indicates that fluphenazine decanoate 5 mg (versus 25 mg) every 2 weeks is effective for at least the first year. In addition, patients report feeling better when they take the lower dose. A dose-comparison study with haloperidol in newly admitted patients indicates that a 20 mg daily dose has neurotoxic effects. A similar dose-comparison study with oral fluphenazine indicates that a 5 mg daily dose is efficacious over a 3-week period. Thus, both inpatients and outpatients can be managed on doses that were formerly regarded as homeopathic. Patients taking low doses have fewer side effects (particularly less akinesia) and probably fewer dysphoric emotions than patients taking high doses, although they improve at a slower rate.
Similar articles
-
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.J Psychiatry Neurosci. 1994 Jul;19(4):254-64. J Psychiatry Neurosci. 1994. PMID: 7918346 Free PMC article. Review.
-
Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.Acta Psychiatr Belg. 1982 Mar-Apr;82(2):216-23. Acta Psychiatr Belg. 1982. PMID: 7180558
-
The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.Int J Geriatr Psychiatry. 2002 Nov;17(11):1012-7. doi: 10.1002/gps.740. Int J Geriatr Psychiatry. 2002. PMID: 12404650
-
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.Schizophr Res. 2010 Jun;119(1-3):153-9. doi: 10.1016/j.schres.2010.02.1066. Epub 2010 Mar 26. Schizophr Res. 2010. PMID: 20347267
-
Dose response of prophylactic antipsychotics.J Clin Psychiatry. 1993 Mar;54 Suppl:24-30. J Clin Psychiatry. 1993. PMID: 8097195 Review.
Cited by
-
Depot haloperidol decanoate for schizophrenia.Cochrane Database Syst Rev. 2000;1999(2):CD001361. doi: 10.1002/14651858.CD001361. Cochrane Database Syst Rev. 2000. PMID: 10796438 Free PMC article.
-
Fluphenazine decanoate (depot) and enanthate for schizophrenia.Cochrane Database Syst Rev. 2015 Feb 5;2015(2):CD000307. doi: 10.1002/14651858.CD000307.pub2. Cochrane Database Syst Rev. 2015. PMID: 25654768 Free PMC article.
-
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.Cochrane Database Syst Rev. 2015 Jan 16;1(1):CD009831. doi: 10.1002/14651858.CD009831.pub2. Cochrane Database Syst Rev. 2015. PMID: 25592299 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical